A Prescription Drug User Fee Act target date of July 26, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...
A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.
Halozyme Therapeutics HALO announced that it has entered into a definitive agreement with Antares Pharma ATRS to acquire the latter for approximately $960 million. The acquisition will add Antares’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback